Literature DB >> 2576951

Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma.

A Libroia, U Verga, G Di Sacco, M Piolini, F Muratori.   

Abstract

We have studied seven subjects with medullary thyroid carcinoma. Each had elevated basal serum calcitonin (CT) levels following total thyroidectomy. After subcutaneous administration of 100 micrograms of SMS 201-995, blood samples were collected at 60-minute intervals for six hours. Two patients showed a marked decrease of CT levels (patient A: baseline 565 pg/mL, nadir 150 pg/mL; patient B: baseline 1,632 pg/mL, nadir 416 pg/mL). The other five patients showed no significant change in comparison with saline infusion. Two patients were treated with SMS 201-995 (300 micrograms/day) for 90 days. One of these patients responded to the acute SMS 201-995 test and had CT levels persistently 50% lower than pretreatment values during this 90-day period. The other patient, whose CT levels did not decrease during the acute test, had persistently high values during this 90-day period but had relief of watery diarrhea even after the therapeutic trial was discontinued.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2576951

Source DB:  PubMed          Journal:  Henry Ford Hosp Med J        ISSN: 0018-0416


  2 in total

1.  Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities.

Authors:  S Inanir; M Unlü; B Okudan; E Cila; S Atik
Journal:  Eur J Nucl Med       Date:  1996-08

2.  Somatostatin analogs in the treatment of medullary thyroid carcinoma.

Authors:  J J Díez; P Iglesias
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.